• Alnylam (ALNY) is the clearest potential value opportunity: the speaker viewed it as attractive near $160, citing profitability and a low valuation, but weigh slowing growth and drug-development risk.
• Palantir (PLTR) drew strong praise for its quarter, though it fell 5%; consider the results alongside valuation and market expectations before buying.
• Neurocrine (NBIX) has promising commercial momentum from Ingrezza and Crenessity, but the discussion offered no valuation or specific entry point.
• Treat Tesla (TSLA) and Micron (MU) shorts cautiously: both were rallying, and the discussion provided limited support for the bearish positions.

Palantir (PLTR)

• The speaker said he was long Palantir and described its quarter and reported numbers as “amazing” and “incredible.”
• The stock was later noted as down 5% during the session, despite the positive view.

Takeaways

• The discussion is bullish on Palantir’s business results, but it gives no valuation analysis or price target. The positive reaction to the quarter should be weighed against the stock’s price and expectations.

Apple (AAPL)

• Apple’s fiscal Q4 results were described as broadly solid: the speaker cited 12% revenue growth, strong product performance, and $145 billion in cash flow from operations.
• Services growth slowed somewhat; iPad and wearables were weaker, while the speaker called services Apple’s biggest business.
• The speaker thought the stock was expensive at about 34 times earnings, and said he would not pay a multiple in the high 20s. He was uncertain where future growth would come from.
• He also pointed to rising R&D spending and the possibility that a new device or product from a competitor could challenge the iPhone. At the same time, he said Apple’s financials were clean and that recent revenue growth had been strong.
• Apple was noted as down 3% during the session.

Takeaways

• The discussion presents Apple as a financially strong company with solid recent growth, but valuation and uncertainty about future products are reasons for caution.
• Investors considering the stock could focus on whether iPhone demand and new products can sustain growth at its current valuation.

Alnylam Pharmaceuticals (ALNY)

• The speaker discussed Alnylam at about $160, compared with roughly $240 relatively recently, and questioned why the stock had fallen so sharply.
• He estimated its market capitalization or enterprise value at about $20 billion and described the valuation as roughly five times earnings, while noting this was after cost of goods but before other costs.
• Alnylam had reiterated guidance. The speaker said revenue growth was slowing, but that excluding an unusual collaboration item, revenue was still growing rapidly. He also described the company as profitable and questioned why the market was selling it off so heavily.
• The transcript mentions pipeline opportunities, including a potential Huntington’s disease drug, but the speaker said its promise would depend on whether it worked; he also referenced favorable preclinical data as something another person had mentioned.

Takeaways

• The speaker’s view was bullish on valuation and current profitability, but he also acknowledged slowing growth and the uncertainty of drug development.
• The discussion suggests examining the company’s underlying revenue growth separately from collaboration-related revenue and treating pipeline prospects as uncertain rather than established value.

Neurocrine Biosciences (NBIX)

• The speaker praised Ingrezza as an exceptional drug and said Crenessity was also selling well.
• He described Neurocrine as having grown into a substantial commercial biotech business, with about $1 billion in quarterly revenue.
• He had not updated his model recently and was uncertain about one pipeline program’s approval prospects, adding that approval should not be assumed impossible.

Takeaways

• The comments are positive about Neurocrine’s commercial products, particularly Ingrezza, but they do not provide a valuation or a specific recommendation.
• Investors may want to distinguish revenue from established products from the more uncertain contribution of pipeline drugs.

Tesla (TSLA)

• The speaker initially said he was short Tesla, but also noted that Tesla had been the strongest performer among the large technology stocks.
• He said he was unsure what was supporting the strength and floated a possible assumed merger with SpaceX as one explanation, not as a confirmed event.

Takeaways

• The stated position was bearish, but the speaker acknowledged strong momentum and did not identify a firm catalyst for it.
• The SpaceX connection was speculative in the discussion; it should not be treated as a confirmed transaction or investment thesis.

Micron Technology (MU)

• The speaker initially said he was short Micron.
• Later, he noted that Micron was catching a rally, without giving a further explanation or changing his stated view.

Takeaways

• The transcript records a short position but provides little supporting analysis. The later rally is a reminder that the position may face near-term pressure.

Intel (INTC)

• The speaker said Intel had “probably” found a bottom for the time being, but was not sure. He noted that the stock had not wanted to fall below $60.
• He also commented that AMD was outperforming Intel.

Takeaways

• The view is tentative rather than a firm bullish call. The discussion points to $60 as a level the speaker was watching, not as a price target or guaranteed floor.

Advanced Micro Devices (AMD)

• AMD was noted as up 5% during the session.
• The speaker contrasted AMD’s performance with Intel, saying AMD had been “beating the crap out of” Intel.

Takeaways

• The transcript highlights AMD’s relative strength versus Intel, but offers no valuation analysis or specific recommendation.

NVIDIA (NVDA)

• NVIDIA was mentioned at $208, and the speaker said his computing setup was largely driven by NVIDIA machines.
• No specific investment view or valuation analysis was provided.

Takeaways

• The mention reflects NVIDIA’s role in the speaker’s computing setup, not a direct stock recommendation. The transcript does not provide enough analysis to draw a stronger investment conclusion.

SanDisk (SNDK)

• SanDisk was noted as being “a little” higher during the session, alongside Micron’s rally.
• No company-specific analysis was provided.

Takeaways

• This was a brief market update rather than an investment thesis; the transcript does not offer a basis for a directional view.

Shopify (SHOP)

• Shopify was noted as down 10% during the session.
• The speaker said he had not yet reviewed its earnings.

Takeaways

• The stock move was mentioned without analysis of the results or business outlook. The transcript does not support a buy-or-sell conclusion.

Bloom Energy (BE)

• Bloom was noted as up 10% during the session, without further discussion.

Takeaways

• The mention is only a price-move observation; no investment thesis or recommendation was provided.

Moderna (MRNA)

• Asked whether Moderna was a short, the speaker said he was not sure, and referred to a price of $230.

Takeaways

• The speaker did not give a clear bullish or bearish view. The cited price is not presented as a target.

Hyperliquid (HYPE)

• The speaker said he was pretty bullish on Hyperliquid, describing it as a platform for decentralized leverage.
• He highlighted the ability to trade stocks on the platform with 10x leverage and mentioned having made “like 20 in a day,” without specifying a unit or timeframe beyond that day.

Takeaways

• The speaker’s positive view centers on the platform’s leveraged stock-trading product. Anyone evaluating it should understand how leverage works and the potential for losses to be magnified.

Anthropic (Private company; no public ticker mentioned)

• The speaker said whether he would buy Anthropic stock depends on the price: he would buy at $1, but not at a $10 trillion valuation.

Takeaways

• The key point is that enthusiasm for a company does not by itself justify an investment; valuation matters. No actual price or valuation for an available investment was discussed.

Spruce (Unclear company or ticker)

• When asked to choose one stock, the speaker responded, “Probably Spruce,” but provided no context or explanation.

Takeaways

• The reference is too brief and ambiguous to support an investment conclusion or identify a specific company confidently.

Commercial biotechnology and pharmaceutical businesses

• Beyond Alnylam and Neurocrine, the speaker discussed commercial biotech generally, noting that drug revenue growth can slow as a company reaches the patients who need a treatment.
• He also said research and development costs at biotech companies can complicate earnings comparisons because they are expensed under accounting rules, even though he views R&D more like an investment in future products.

Takeaways

• For drug companies, the discussion suggests looking beyond headline revenue growth: consider the maturity of existing drugs, profitability, and whether future products can replace slowing growth.
• Pipeline potential can be meaningful, but the transcript also emphasizes that drug success is not assured.